« Previous article
Biobank Graz Reports...
Biobank Graz Reports...
Next article »
Life Technologies to...
Life Technologies to...
21st March 2012 Content supplied by: Meridian Life Science
New Monoclonal Antibodies to Chikungunya Virus (CHIKV).
Meridian Life Science, Inc. (MLS) has released three new monoclonal antibodies to Chikungunya virus (CHIKV).
These antibodies are non cross-reactive to:
- Eastern Equine Encephalitis (EEE)
- Western Equine Encephalitis (WEE)
- Venezuelan Equine Encephalitis (VEE)
- and, other Arborviruses
Suitable for ELISA and IFA. Immunogen was recombinant Chikungunya virus lysate.Chikungunya virus (CHIKV) is an insect-borne viral disease transmitted to humans by the bite of an infected mosquito. Diagnosis of Chikungunya fever can be confirmed by the detection of the virus, viral RNA, or specific antibodies in patient samples. Serological tests such as ELISA confirm the presence of IgM and IgG anti-chikungunya antibodies. It is possible to isolate the virus from the blood after the first few days of infection; however IgM antibody levels are the highest three to five weeks after onset and are maintained at detectable levels for about two months.
RT-PCR methods are also available but have been reported to have variable sensitivity. Other possible laboratory tests include immunofluorescence assays, plaque reduction neutralization (PRN) tests and Hemagglutination-inhibition tests.
For Research Use Only. Not for Use in Diagnostic Procedures.
Please note : Any products described on this page are
for Research Use Only and not intended for clinical diagnostic procedures unless otherwise stated.
Date Published: 21st March 2012
Related news
« Previous article
Biobank Graz Reports On Micronic
Biobank Graz Reports On Micronic
Next article »
Life Technologies to Distribute Ceeram
Life Technologies to Distribute Ceeram